These favorable outcomes substantiate the implication of type 2 cytokines in steering the pathogenesis of PN and endorse the targeting of the IL-4/IL-13 axis as an innovative therapeutic approach for individuals with PN [5]. Here, IL13 is linked to poikiloderma with neutropenia.